Hi Eqz & All,
I’m sorry, but haven’t had a lot of time for research lately (outside of work). Another beloved family member has not long passed (3 family members recently, that’s enough for the next 10 years, ambitious & sad, yes).
The funeral last week & conversely now helping out planning 100th birthday party for my Nan this weekend! Never get this chance again & do my best.
I think if anything to look at accounts receivable is to go back & look at older ANNs, Both analytics & for R&D. I think something that shouldn’t be forgotten is the biosimilar MAB trial (for Xolair, Omalizumab) we are doing. Sometimes all funds paid is not until later in the clinical trial.
I don’t think it’s Janssen that owes us, as something that stuck in my mind from the initial ANN, is that both companies would be bearing their own costs to complete this collaboration of a very large retrospective clinical trial, with blood sample analysis of around 4000 clinical trial patients in CREDENCE (completed) & potentially more with Janssen’s CVD study CANVAS (completed) that has been mentioned as well as a potential study extension to look at predicting that indication with PromarkerD as well.
So I copied this for everyone’s convenience:
https://www.asx.com.au/asxpdf/20181126/pdf/440mb86sdpmk7m.pdfThis has potential benefit to both parties, READ the ANNS new people! There have been updates. It’s been a mammoth effort by PIQ, & we are due on that news any day soon between now & March 2020.
Definately with CE Mark & approvals in EU, It makes sense to have a few months grace for FDA approval for PromarkerD, post clinical trials with Janssen.
We should have some news on Janssen/Mundipharma’s application for CKD/CVD indication in EU sometime very soon (this month likely) for Invokana. Canada have recently approved & FDA & last year for the same extra indications in the USA. For anyone that doesn’t know, the trials that achieved this approval, PIQ have been working on blood samples this last year, & it is groundbreaking. It will give PromarkerD the highest credibility with such a large Ph3 sample size in an already available drug on market for diabetes in the use of this drug & class of drugs in other indications.
There has been a big spend on equipment & plant this quarter (~1.3 million), hence it looked a bit bad, but necessary to move forward. We discussed this previously, & I do believe MABs will be a big earner for PIQ, if not already, both in Cancer research & other indications. Definately the way medicine is moving forward in many indications.
Just a few thoughts. GLTAH
(20min delay)